Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

61. Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth

Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Scientific Impact Paper No. 29 August 2011Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth 1. Background The prevalence of preterm birth is increasing. 1 While the survival of infants born preterm has improved, 2 the prevalence of cerebral palsy has risen. 3 The incidence of cerebral palsy decreases significantly with increasing (...) to reduce the effects of this disabling condition on individuals, families, health care and society. 2. Neuroprotection In the late 1990s studies of infants born to mothers given magnesium sulphate to prevent eclamptic seizures or as tocolysis showed a reduction in rates of cystic periventricular leucomalacia (PVL) and cerebral palsy. In those babies born preterm and exposed to magnesium sulphate 8 the odds ratio for cerebralpalsywas0.14(95%CI0.05–0.51). 9 Althoughtheexactmechanismofactionofmagnesium

2011 Royal College of Obstetricians and Gynaecologists

62. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis

Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Cahill AG, Odibo AO, Stout MJ, Grobman WA, Macones GA, Caughey AB Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of magnesium treatment, for pregnant women at high risk of delivery before 32 weeks gestation, for the prevention of cerebral palsy in pre-term infants. Based on the evidence available, magnesium

2011 NHS Economic Evaluation Database.

63. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study

Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

64. Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy (Abstract)

Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy Preparation regimens for morning colonoscopy are suboptimal. The aim of this study was to test the efficacy and tolerance of a split-dose magnesium citrate-low-volume (2 liters) polyethylene glycol (PEG) regimen for morning colonoscopy.A total of 232 patients were randomly assigned to receive 4 liters PEG (...) (day before procedure; group 1, n=79), 2 liters PEG (day before procedure) followed by another 2 liters PEG (day of procedure; group 2, n=80), or magnesium citrate (250 ml, day before procedure) followed by 2 liters PEG (day of procedure; group 3, n=73). The quality of bowel cleansing, tolerability, and adverse effects in group 3 were compared with those in groups 1 and 2.Satisfactory bowel preparation was more frequently reported for group 3 than for group 1 (75% vs. 51%, P=0.001) and was similar

2010 EvidenceUpdates Controlled trial quality: uncertain

65. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study

Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

66. SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution

SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution Drug Approval Package: SUPREP (sodium sulfate, potassium sulfate, magnesium sulfate) NDA #022372 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution Company: Braintree Laboratories, Inc. Application No.: 022372 Approval Date: 08/05/2010 Persons with disabilities having problems

2010 FDA - Drug Approval Package

67. Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets

Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Company: Pozen Application No.: 022511 Approval Date: 4/30/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

68. Magnesium Sulfate for Asthma Attack

Magnesium Sulfate for Asthma Attack Magnesium Sulfate for Asthma Attack – TheNNTTheNNT Intravenous Magnesium Sulfate Given During an Asthma Attack 3 for prevented hospital admission In Summary, for those who took the magnesium: Benefits in NNT 67% saw no benefit 33.3% of severe asthmatics were helped by preventing hospital admission 1 in 3 were helped (preventing hospital admission if patient is a "severe asthmatic") None were helped (preventing hospital admission if patient is not a "severe (...) asthmatic") Harms in NNT 0% of severe asthmatics were harmed by serious side effects 100% of non-severe asthmatics were neither helped nor harmed None were harmed (serious side effects, vital sign abnormalities) View As: NNT % Source: Efficacy Endpoints: Hospital admission Harm Endpoints: Tachycardia, tremor Narrative: This review included 7 trials, (N = 665) of which 5 were adult and 2 pediatric. Magnesium sulfate was administered early in the study period, in the first 60 minutes in 5 of the studies

2010 theNNT

69. Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials

Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

70. Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial Full Text available with Trip Pro

Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial The goal was to study whether postnatal magnesium sulfate infusion could improve neurologic outcomes at discharge for term neonates with severe perinatal asphyxia.Forty term (> or =37 weeks of gestation) neonates with severe perinatal asphyxia were studied in a prospective, longitudinal, placebo-controlled trial. Patients were assigned randomly to receive either 3 doses of magnesium sulfate infusion at 250 mg (...) of 20) of patients had severe encephalopathy. The mean serum magnesium concentration in the treatment group remained at > or =1.2 mmol/L for 72 hours after the first infusion. At discharge, 22% (4 of 18) of infants in the treatment group had neurologic abnormalities, compared with 56% (10 of 18) of infants in the placebo group. Also, neuroimaging (head computed tomography) performed on day 14 yielded abnormal findings for fewer infants in the treatment group than in the placebo group (16% vs 44

2009 EvidenceUpdates Controlled trial quality: predicted high

71. Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants

Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Article Text Therapeutics Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Statistics from Altmetric.com Question

2009 Evidence-Based Medicine

72. Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery

Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery Clinical question How effective is magnesium sulphate as a neuroprotective agent when given to women considered at risk of preterm delivery? Bottom line (...) Antenatal magnesium sulphate therapy given to women at risk of preterm delivery, substantially reduced the risk of cerebral palsy in their child (NNT* 63). There was also a significant reduction in the rate of substantial gross motor dysfunction. The loading dose given was 4g or 6g IV, with a maintenance dose varying from nil (2 studies) to 1g/hour (1 study) and 2-3 g/hour (2 studies). The magnesium sulphate was given 24 hours prior to delivery in 3 studies, with no specific time interval reported in 2

2009 Cochrane PEARLS

73. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis

Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

74. A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate

A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

75. Intraarticular injection of magnesium sulphate and/or bupivacaine for postoperative analgesia after arthroscopic knee surgery (Abstract)

Intraarticular injection of magnesium sulphate and/or bupivacaine for postoperative analgesia after arthroscopic knee surgery Intraarticular bupivacaine is often used for prevention of pain after arthroscopic knee surgery. Intraarticular magnesium, a N-methyl-D-aspartate receptor blocker, would be of particular interest in either producing postoperative analgesia or enhancing the analgesic effect of intraarticular bupivacaine. We designed this study to determine whether intraarticular magnesium (...) sulfate or bupivacaine results in a decrease in visual analog scale (VAS) score followed by a decrease in analgesic requirement and whether their combination would provide more reduction in VAS, and subsequently less analgesic requirement, than either drug alone.One-hundred and eight patients undergoing arthroscopic meniscectomy were randomized blindly into one of four parallel groups. The saline placebo group (group S) received 20 mL of isotonic saline, and the magnesium group (group M) received 20

2008 EvidenceUpdates Controlled trial quality: uncertain

76. Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension

Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Drug Approval Package: Nexium (esomeprazole magnesium) NDA #022101 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Company: AstraZeneca LP Application No.: 022101 Approval Date: 2/27/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2008 FDA - Drug Approval Package

77. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. Full Text available with Trip Pro

A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy.In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching (...) placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age.A total of 2241 women underwent randomization. The baseline characteristics were similar in the two groups. Follow-up was achieved for 95.6% of the children. The rate of the primary outcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and 11.7%, respectively; relative risk, 0.97

2008 NEJM Controlled trial quality: predicted high

78. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton G K, Tanajewski L, Turner D, Price A CRD summary RCTs directly comparing intravenous magnesium sulphate with sotalol were not identified, but the authors did conclude that intravenous magnesium is effective in preventing atrial fibrillation in patients undergoing coronary artery bypass graft when compared to controls. This was a well conducted piece of research, which considered limitations with the included studies. The authors' conclusions are likely to be reliable. Authors

2008 DARE.

79. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton GK, Tanajewski L, Turner D, Price A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. Southampton

2008 Health Technology Assessment (HTA) Database.

80. Magnesium sulfate for persistent pulmonary hypertension of the newborn. (Abstract)

Magnesium sulfate for persistent pulmonary hypertension of the newborn. Persistent pulmonary hypertension of the newborn (PPHN) occurs in approximately 1.9 per 1000 newborns and may be more frequent in developing countries. There is strong evidence for the use of inhaled nitric oxide (iNO) and extra corporeal membrane oxygenation (ECMO) in the treatment of PPHN. However, many developing countries do not have access or the technical expertise required for these expensive therapies. Magnesium (...) sulfate is a potent vasodilator and hence has the potential to reduce the high pulmonary arterial pressures associated with PPHN. If magnesium sulfate were found to be effective in the treatment of PPHN, this could be a cost effective and potentially life-saving therapy.To evaluate the use of magnesium sulfate compared with placebo or standard ventilator management alone, sildenafil infusion, adenosine infusion, or inhaled nitric oxide on mortality or the use of backup iNO or ECMO in term and near

2007 Cochrane